X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (76) 76
humans (66) 66
oncology (66) 66
cancer (53) 53
male (52) 52
female (49) 49
middle aged (45) 45
aged (38) 38
adult (33) 33
tumors (31) 31
clinical trials (30) 30
patients (28) 28
neoplasms - drug therapy (25) 25
chemotherapy (24) 24
treatment outcome (21) 21
aged, 80 and over (18) 18
antineoplastic agents - therapeutic use (18) 18
survival (16) 16
therapy (16) 16
analysis (15) 15
prospective studies (15) 15
immunotherapy (14) 14
mutation (14) 14
risk factors (14) 14
solid tumors (14) 14
antineoplastic agents - adverse effects (13) 13
medical research (13) 13
metastasis (13) 13
toxicity (13) 13
care and treatment (12) 12
hematology, oncology and palliative medicine (12) 12
young adult (12) 12
melanoma (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
pharmacology & pharmacy (10) 10
prognosis (10) 10
antimitotic agents (9) 9
antineoplastic agents (9) 9
cell lung-cancer (9) 9
multivariate analysis (9) 9
predictive value of tests (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
biopsy (8) 8
clinical trials, phase i as topic (8) 8
dose-response relationship, drug (8) 8
gastroenterology & hepatology (8) 8
life sciences (8) 8
lung cancer (8) 8
medicine, experimental (8) 8
neoplasms - pathology (8) 8
pharmacokinetics (8) 8
pharmacology (8) 8
proportional hazards models (8) 8
research (8) 8
retrospective studies (8) 8
time factors (8) 8
abridged index medicus (7) 7
drug development (7) 7
gemcitabine (7) 7
inhibitors (7) 7
kaplan-meier estimate (7) 7
lung neoplasms - drug therapy (7) 7
medicine & public health (7) 7
metastases (7) 7
neoplasms - genetics (7) 7
studies (7) 7
bevacizumab (6) 6
biomarkers (6) 6
cancer patients (6) 6
carcinoma, non-small-cell lung - drug therapy (6) 6
clinical trials as topic (6) 6
colorectal cancer (6) 6
disease-free survival (6) 6
drug administration schedule (6) 6
drug therapy (6) 6
expression (6) 6
follow-up studies (6) 6
genomics (6) 6
immune checkpoint (6) 6
inhibition (6) 6
lung-cancer (6) 6
metastatic breast-cancer (6) 6
mortality (6) 6
neoplasms - mortality (6) 6
nivolumab (6) 6
open-label (6) 6
phase i (6) 6
phase i trial (6) 6
safety (6) 6
safety engineering (6) 6
sorafenib (6) 6
surgery (6) 6
trial (6) 6
tyrosine (6) 6
[ sdv.can ] life sciences [q-bio]/cancer (5) 5
biomarkers, tumor - genetics (5) 5
cancer therapies (5) 5
carcinoma (5) 5
deoxycytidine - analogs & derivatives (5) 5
deoxyribonucleic acid--dna (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 8, pp. 726 - 736
Journal Article
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 10/2017, Volume 76, Issue 10, pp. 1747 - 1750
ObjectivesImmune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1 (PD-1) have... 
MELANOMA | MANAGEMENT | TOXICITIES | LEAGUE | COLLEGE | RHEUMATOLOGY | NIVOLUMAB | BLOCKADE | CLASSIFICATION CRITERIA | CANCER | IPILIMUMAB | Antibodies, Monoclonal, Humanized - adverse effects | Polymyalgia Rheumatica - blood | Polymyalgia Rheumatica - chemically induced | Arthritis, Rheumatoid - blood | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Peptides, Cyclic - immunology | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Arthritis, Rheumatoid - chemically induced | Polymyalgia Rheumatica - drug therapy | B7-H1 Antigen - antagonists & inhibitors | Antineoplastic Agents - adverse effects | Arthritis, Rheumatoid - drug therapy | Aged, 80 and over | Antibodies - blood | Female | Aged | Retrospective Studies | CTLA-4 Antigen - antagonists & inhibitors | Corticoids | Disease | PD-1 protein | Arthralgia | Lung cancer | Clinical trials | Antibodies | Cytotoxicity | Mesothelioma | Lymphocytes T | Metastasis | Cancer therapies | Immunosuppressive agents | Proteins | Immunotherapy | Rheumatism | Immunoglobulins | Antiinflammatory agents | Cell survival | Psoriasis | Internal medicine | Rheumatic diseases | Rheumatology | Melanoma | Inflammation | Citrulline | Patients | Rheumatoid factor | Immune checkpoint | Cell death | Rheumatoid arthritis | Collaboration | Polymyalgia rheumatica | Ligands | Autoimmune diseases | Apoptosis | Cancer
Journal Article
The Lancet Oncology, ISSN 1470-2045, 09/2018, Volume 19, Issue 9, pp. 1180 - 1191
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2014, Volume 32, Issue 2, pp. 68 - 75
Purpose Human epidermal growth factor (HER) -mediated signaling is critical in many cancers, including subsets of breast and lung cancer. HER family members... 
CELL LUNG-CANCER | HKI-272 | THERAPY | TRASTUZUMAB | ONCOLOGY | METASTATIC BREAST-CANCER | TYROSINE KINASE INHIBITOR | HER2 STATUS | MUTATIONS | EXPRESSION | EGFR | Neoplasms - metabolism | Lung Neoplasms - drug therapy | Nausea - chemically induced | Receptor, ErbB-2 - genetics | TOR Serine-Threonine Kinases - metabolism | Area Under Curve | Humans | Lung Neoplasms - metabolism | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Phosphatidylinositol 3-Kinases - metabolism | Diarrhea - chemically induced | Quinolines - administration & dosage | Breast Neoplasms - metabolism | Dose-Response Relationship, Drug | Quinolines - pharmacokinetics | Neoplasms - genetics | Female | Sirolimus - adverse effects | Lung Neoplasms - genetics | Sirolimus - analogs & derivatives | Anemia - chemically induced | Treatment Outcome | Sirolimus - pharmacokinetics | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Sirolimus - administration & dosage | Breast Neoplasms - genetics | Gene Amplification | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Stomatitis - chemically induced | Aged | Mutation | Quinolines - adverse effects | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2019, p. clincanres.2035.2019
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2017, Volume 23, Issue 10, pp. 2423 - 2432
Purpose: Chk1 inhibition potentiates DNA-damaging chemotherapy by overriding cell-cycle arrest and genome repair. This phase I study evaluated the Chk1... 
BREAST-CANCER | TRIAL | DOSE-ESCALATION | IMPACT | THERAPY | ONCOLOGY | OVARIAN-CANCER | CHK1 INHIBITOR | DNA-REPLICATION | CELL-DEATH | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Triple Negative Breast Neoplasms - drug therapy | Drug-Related Side Effects and Adverse Reactions - pathology | Dose-Response Relationship, Drug | Melanoma - genetics | Triple Negative Breast Neoplasms - pathology | Adult | Deoxycytidine - adverse effects | Female | Piperidines - administration & dosage | Deoxycytidine - administration & dosage | Checkpoint Kinase 1 - antagonists & inhibitors | Melanoma - pathology | Disease-Free Survival | Triple Negative Breast Neoplasms - genetics | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Melanoma - drug therapy | Piperidines - adverse effects | Aged | Checkpoint Kinase 1 - genetics | Deoxycytidine - analogs & derivatives | Gemcitabine | Toxicity | p53 Protein | DNA damage | Genomes | Dyspnea | Vomiting | Syncope | Bone marrow | Inhibition | Deoxyribonucleic acid--DNA | Neutropenia | Thrombocytopenia | Alanine | Anemia | CHK1 protein | Melanoma | Fatigue | Radioactive half-life | Nausea | Breast cancer | Pharmacology | Patients | Fever | Chemotherapy | Inhibitors | Experimental design | Alanine transaminase | Biomarkers | Solid tumors | Mutation | Pharmacokinetics | Respiration | Tumors | Cancer
Journal Article
British Journal of Cancer, ISSN 0007-0920, 10/2018, Volume 119, Issue 8, pp. 937 - 939
BACKGROUND: Reliable evaluation of treatment benefit in early phase clinical trials is necessary. The time to progression ratio (TTPr), which compares... 
END-POINTS | TARGETS | ONCOLOGY | TUMORS | Medical research | Effectiveness | Clinical trials | Calibration | Two phase | Patients | Guidelines | Cancer | Brief Communication
Journal Article
Gastroenterology, ISSN 0016-5085, 2009, Volume 137, Issue 2, pp. 541 - 548
Journal Article